^
Association details:
| Biomarker: | KLF4 K409Q |
|---|---|
| Cancer: | Meningioma |
| Drug: | Torisel (temsirolimus) (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KLF4K409Q–mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment
Excerpt:
When treated with Temsirolimus in the skull base meningioma model, median OS in both groups (KLF4wt and KLF4K409Q) was prolonged by 9 days...p < 0.001) in comparison with non-treated mice...the median survival of the KLF4K409Q group was further increased by 2.5 days (26 vs 28.5 days, p= 0.050)...Taken together, these data identify Temsirolimus as a promising agent preferentially in KLF4K409Q skull base tumors.
DOI:
10.1186/s40478-020-00912-x
